Yes we can treat cancer even in the poorest countries
So says Ian Magrath and his INCTR partners, and they have the evidence to prove it that will be crucial to the success of current efforts to stem the rise of cancer in the developing [more]
2010
When the trial you need is just over the border
The bureaucratic obstacles that often prevent European cancer patients from joining clinical trials in other Member States came under the spotlight recently in the case of a young woman with melanoma. Download full article
Jaap Verweij: an intelligent approach to drug
Jaap Verweij, head of medical oncology and an early-phase trials expert at the Erasmus University Medical Centre in Rotterdam invites you to reappraise the way we are going about improving cancer therapies. Download full article
The treatment of gastrointestinal stromal tumours (GIST)
Better understanding of the different mutations that drive GIST is leading to new paradigms of tailored treatment that break many norms of chemotherapy, especially in management of progression. Download full article
Who’s who in the world of personalised cancer treatments?
The number of drugs being developed to target specific mutations is rising steadily. But finding which targeted therapies work best for which sets of mutations is proving an elusive goal. Download full article
Blazing a trail in a new type of research
When confronted with the novel gene technology of the early ’70s, molecular biologist Axel Ullrich posed the question: what use can this be to medicine? Opening the door to translational research Download full article
From unwanted interference to indispensable partner
As founding president of Europa Donna, Gloria Freilich helped transform attitudes towards patient advocacy. She would like to see further progress and advises that her softly softly approach is the way to go. Download full [more]
Trials and tribulations in primary CNS lymphoma
A minority of patients with primary central nervous system lymphoma achieve a complete response to therapy andmost patients have a poor prognosis.A recent randomised phase II trial demonstrated that the addition of high-dose cytarabine to [more]
Androgen deprivation therapy for prostate cancer: true love or heartbreak?
The addition of hormonal therapy to radiation therapy improves survival inmenwith unfavourable risk prostate cancer.Yet,menwith prostate cancer have higher rates of non-cancer death than the general population andmost will die fromcauses other than their indexmalignancy. [more]
Newsround
Selected reports edited by Janet Fricker Download full article
Should you respect a dying wish?
Some terminally ill cancer patients, seeing only suffering and indignity ahead, want to die at a time and in a manner of their own choosing. But how does legal backing for assisted dying impact on [more]
Future directions in multimodality therapy for NSCLC
Patients with stage III non-small-cell lung cancer comprise a heterogeneous population; the role of surgical resection in this setting has been controversial. Albain and colleagues recently demonstrated that trimodality therapy with lobectomy had clinical benefit [more]
Sunitinib versus interferon-á in metastatic RCC
Motzer and colleagues presented updated results from a multicentre, phase III trial of sunitinib versus interferon-á as first-line treatment for patients with metastatic renal-cell carcinoma. The observed improvement in overall survival for patients treated with [more]